Richard A. Lange, MD, MBA
July 11th, 2014
Do FFR and IVUS Feed the Elephant?
Richard A. Lange, MD, MBA and L. David Hillis, MD
Rick Lange and David Hillis wonder whether the debate about the role of FFR and IVUS in patient selection for PCI is a red herring in the larger issue of revascularization in patients with stable CAD.
June 4th, 2014
Transcatheter Mitral Valve Programs: No Volume Data
Richard A. Lange, MD, MBA and L. David Hillis, MD
The Society for Cardiac Angiography and Interventions (SCAI), the American Association for Thoracic Surgery (AATS), the American College of Cardiology (ACC), and the Society of Thoracic Surgeons (STS) recently joined together to provide recommendations for institutions that are considering starting and/or maintaining a transcatheter mitral valve (MV) program. Unlike PCI, for which abundant data show a […]
November 18th, 2013
What’s the Moral from CORAL?
Richard A. Lange, MD, MBA and L. David Hillis, MD
Rick Lange and David Hills ask, “Should we stop screening for renal artery stenosis?”
October 31st, 2013
Does OPTIMIZE Reveal the Optimal DAPT Time Frame?
Richard A. Lange, MD, MBA and L. David Hillis, MD
Rick Lange and David Hillis pose several important questions triggered by the OPTIMIZE findings.
September 20th, 2013
My Stent Is Better Than Your Stent
Richard A. Lange, MD, MBA and L. David Hillis, MD
Interventionalists have many choices when it comes to coronary stents. Rick Lange and David Hillis want to know: “How do you decide which stent to use?”
September 13th, 2013
Should We Treat Nonculprit Lesions During PCI for STEMI?
David S Wald, MA MD FRCP, Richard A. Lange, MD, MBA and L. David Hillis, MD
CardioExchange’s Rick Lange and David Hillis interview David Wald about his group’s recently published findings from the PRAMI trial of “preventive” PCI in STEMI patients. Based on results of previous nonrandomized, observational studies, stenting non-infarct coronary stenoses during primary PCI has been discouraged. The Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial in 465 STEMI patients assessed whether […]
September 1st, 2013
Inside the ACCOAST Trial of Pretreatment Prasugrel
Gilles Montalescot, MD, PhD, John Ryan, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD
Gilles Montalescot, lead investigator of the ACCOAST trial, discusses why prasugrel pretreatment did not benefit patients with non–ST-segment elevation acute coronary syndromes.
August 28th, 2013
Platelet Reactivity Testing: Do You or Don’t You?
Richard A. Lange, MD, MBA and L. David Hillis, MD
In light of recent findings from the ADEPT DES study, Richard Lange and David Hillis want to know: Do you test PCI patients for platelet reactivity, and if so, why? React to reactivity in our latest poll.
August 26th, 2013
Practice Variations and Quality: Ask the “Uber” Expert
Richard A. Lange, MD, MBA and Harlan M. Krumholz, MD, SM
In light of reported variation in practice and outcomes of elective PCI, Rick Lange asks Harlan Krumholz to elaborate on what constitutes high-quality decision making.
August 5th, 2013
Poll: What Would You Recommend?
Richard A. Lange, MD, MBA
Take the poll: What would you recommend for a patient who is about to undergo CABG for multivessel CAD and is found to have severe carotid stenosis?
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy